CD33 positivity and MPC-1 negativity appear to be associated with worse outcomes in patients with multiple myeloma treated with bortezomib as induction therapy. A CAR-T therapy for myeloma that is ...
Explore Tebis' Smartops Technology, an innovative solution for automating design and CAM processes, enhancing speed, ...
Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot ...
This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. CARPENTERSVILLE, Ill. – With manufacturing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback